Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Aims & design of the EXCALIBER-RRM study

Sagar Lonial • 26 Aug 2022
IMS 2022
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Iberdomide Lenalidomide Pomalidomide
EXCALIBER-RRMM

Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, comments on the design and aims of EXCALIBER-RRM (NCT04975997), a Phase III study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab versus daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sagar Lonial

1:05
Real-world comparison of RVD vs D-RVD in newly diagnosed transplant-eligible multiple myeloma
Sagar Lonial • 9 Dec 2023
0:45
The addition of daratumumab to RVD deepens treatment responses in t(11;14) multiple myeloma
Sagar Lonial • 9 Dec 2023
1:06
DeRIVE trial update: DId vs DVd in newly diagnosed MM
Sagar Lonial • 9 Dec 2023
0:48
Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myeloma
Sagar Lonial • 7 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals